Activation of spinal cannabinoid CB2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice

Neuroscience

Volumn 250, Issue , 2013, Pages 446-454

  Ikeda, H ^a   Ikegami, M ^a   Kai, M ^a   Ohsawa, M ^a   Kamei, J ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Cannabinoid; Diabetes; Diacylglycerol lipase ; Neuropathic pain; Spinal cord; Streptozotocin

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; L 759656; LIPOPROTEIN LIPASE; LIPOPROTEIN LIPASE ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; LOW DRUG DOSE; MALE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD; STREPTOZOCIN DIABETES; TAIL FLICK TEST;

2-AG; 2-ARACHIDONOYLGLYCEROL; CANNABINOID; DGL-Α; DIABETES; DIACYLGLYCEROL LIPASE Α; I.T.; INTRATHECAL; NEUROPATHIC PAIN; SDS; SODIUM DODECYL SULFATE; SPINAL CORD; STREPTOZOTOCIN; STZ; TBS; TBST; TRIS-BUFFERED SALINE; TRIS-BUFFERED SALINE CONTAINING 0.1% TWEEN-20;

ANIMALS; ARACHIDONIC ACIDS; BENZOXAZINES; BLOTTING, WESTERN; CHROMANS; DIABETES MELLITUS, EXPERIMENTAL; ENDOCANNABINOIDS; GLYCERIDES; INJECTIONS, SPINAL; LIPOPROTEIN LIPASE; MALE; MICE; MICE, INBRED ICR; MORPHOLINES; NAPHTHALENES; NEURALGIA; PAIN MEASUREMENT; PAIN THRESHOLD; REACTION TIME; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SPINAL CORD;

EID: 84882805344     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.07.040     Document Type: Article

References (40)

1. Aring A.M., Jones D.E., Falko J.M. Evaluation and prevention of diabetic neuropathy. Am Fam Physician 2005, 71:2123-2128.
2. Chen S.R., Pan H.L. Antinociceptive effect of morphine, but not μ opioid receptor number, is attenuated in the spinal cord of diabetic rats. Anesthesiology 2003, 99:1409-1414.
3. Clayton N., Marshall F.H., Bountra C., O'Shaughnessy C.T. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 2002, 96:253-260.
4. Doǧrul A., Gül H., Yildiz O., Bilgin F., Güzeldemir M.E. Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett 2004, 368:82-86.
5. Galer B.S., Gianas A., Jensen M.P. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000, 47:123-128.
6. 2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008, 153:319-334.
7. Gul H., Yildiz O., Dogrul A., Yesilyurt O., Isimer A. The interaction between IL-1β and morphine. Possible mechanism of the deficiency of morphine-induced analgesia in diabetic mice. Pain 2000, 89:39-45.
8. 2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 2007, 150:153-163.
9. Hamma A., Sagen J. Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain. Brain Res 2011, 1412:44-54.
10. 2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol 2011, 162:428-440.
11. Hylden J.L., Wilcox G.L. Intrathecal morphine in mice: a new technique. Eur J Pharmacol 1980, 67:313-316.
12. Kamei J., Mizoguchi H., Narita M., Tseng L.F. Therapeutic potential of PKC inhibitors in painful diabetic neuropathy. Expert Opin Invest Drugs 2001, 10:1653-1664.
13. Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009, 89:309-380.
14. Kapur D. Neuropathic pain and diabetes. Diabetes Metab Res Rev 2003, 19:S9-S15.
15. 1 receptor activation inhibits spinal nociceptive transmission in vivo. J Neurophysiol 2001, 86:3061-3064.
16. 1 cannabinoid receptors be selectively targeted for therapeutic gain?. Trends Pharmacol Sci 2008, 30:1-7.
17. Milligan E.D., Watkins L.R. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009, 10:23-36.
18. Morisset V., Urban L. Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. J Neurophysiol 2001, 86:40-48.
19. Morisset V., Ahluwalia J., Nagy I., Urban L. Possible mechanisms of cannabinoid-induced antinociception in the spinal cord. Eur J Pharmacol 2001, 429:93-100.
20. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
21. 2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 2003, 119:747-757.
22. Nyilas R., Gregg L.C., Mackie K., Watanabe M., Zimmer A., Hohmann A.G., Katona I. Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. Eur J Neurosci 2009, 29:1964-1978.
23. Ohsawa M., Nagase H., Kamei J. Role of intracellular calcium in modification of mu and delta opioid receptor-mediated antinociception by diabetes in mice. J Pharmacol Exp Ther 1998, 286:780-787.
24. Ohsawa M., Asato M., Hayashi S.S., Kamei J. RohA/Rho kinase pathway contributes to the pathogenesis of thermal hyperalgesia in diabetic mice. Pain 2011, 152:114-122.
25. Ohsawa M., Mizoguchi H., Narita M., Kamei J., Nagase H., Tseng L.F. Effects of a mu-opioid receptor agonist on G-protein activation in streptozotocin-induced diabetic mice. Eur J Pharmacol 2000, 401:55-58.
26. Romero-Sandoval A., Eisenach J.C. Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 2007, 106:787-794.
27. Romero-Sandoval A., Nutile-McMenemy N., DeLeo J.A. Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology 2008, 108:722-734.
28. Sagar D.R., Burston J.J., Woodhams S.G., Chapman V. Dynamic changes to the endocannabinoid system in models of chronic pain. Philos Trans R Soc B 2012, 367:3300-3311.
29. 2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 2005, 22:371-379.
30. -/- mice in models of acute and persistent pain. Neuropharmacology 2009, 57:235-241.
31. Schreiber A.K., Neufeld M., Jesus C.H.A., Cunha J.M. Peripheral antinociceptive effect of anandamide and drugs that affect the endocannabinoid system on the formalin test in normal and streptozotocin-diabetic rats. Neuropharmacology 2012, 63:1286-1297.
32. Scott D.A., Wright C.E., Angus J.A. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 2004, 109:124-131.
33. 2A receptors. Eur J Pharmacol 2010, 649:183-194.
34. Toth C.C., Jedrzejewski N.M., Ellis C.L., Frey W.H. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. Mol Pain 2010, 6:16.
35. Ulugol A., Karadag H.C., Ipci Y., Tamer M., Dokmeci I. The effect of WIN 55,212-2 a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci Lett 2004, 371:167-170.
36. Ulugol A., Oltulu C., Gunduz O., Citak C., Carrara R., Shaqaqi M.R., Sanchez A.M., Dogrul A. 5-HT7 receptor activation attenuates termal hyperalgesia in streptozotocin-induced diabetic mice. Pharmacol Biochem Behav 2012, 102:344-348.
37. Vera G., López-Miranda V., Herradón E., Martín M.I., Abalo R. Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes. Pharmacol Biochem Behav 2012, 102:335-343.
38. Vinik A.I., Suwanwalaikorn S., Stansberry K.B., Holland M.T., McNitt P.M., Colen L.E. Quantitative measurement of cutaneous perception in diabetic neuropathy. Muscle Nerve 1995, 18:574-584.
39. Zhang J., Hoffert C., Vu H.K., Groblewski T., Ahmad S., O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 2003, 17:2750-2754.
40. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Bonner T.I. Increased mortality, hypoactivity, and hypoanalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 1999, 96:5780-5785.